Literature DB >> 26598098

Implications of Augmented Renal Clearance on Drug Dosing in Critically Ill Patients: A Focus on Antibiotics.

Athena L V Hobbs1, Katherine M Shea2, Kirsten M Roberts3, Mitchell J Daley4.   

Abstract

Augmented renal clearance (ARC) has been reported in approximately 30-65% of patients in the intensive care unit (ICU) despite the presence of a normal serum creatinine concentration. In certain ICU patient populations (e.g., patients with sepsis or trauma), the incidence increases to roughly 50-85%. Risk factors for ARC include the following: age younger than 50-55 years, male sex, higher diastolic blood pressure, fewer comorbidities, and a lower Acute Physiology and Chronic Health Evaluation II (APACHE II) or modified Sequential Organ Failure Assessment (SOFA) score at ICU admission. In addition, patient populations with the highest reported incidence of ARC include those with major trauma, sepsis, traumatic brain injury, subarachnoid hemorrhage, and central nervous system infection. Due to the high incidence of ARC in patients with a normal serum creatinine concentration, clinicians should consider screening ICU patients deemed high risk by using the ARC scoring system or the identification and assessment algorithm provided in this review. In addition, an 8-hour continuous urine collection should be considered to assess a measured creatinine clearance for evaluating the necessity of medication dosage adjustments. There is a clear association between ARC and subtherapeutic antibiotic concentrations as well as literature suggesting worse clinical outcomes; thus, the risk of underdosing antibiotics in a patient with ARC could increase the risk of treatment failure. This review examines strategies to overcome ARC and summarizes current pharmacokinetic and pharmacodynamic literature in patients with ARC in an effort to provide dosing guidance for this patient population.
© 2015 Pharmacotherapy Publications, Inc.

Entities:  

Keywords:  antibiotics; augmented renal clearance; creatinine clearance; critically ill; hyperfiltration; pharmacodynamic dosing; pharmacokinetics

Mesh:

Substances:

Year:  2015        PMID: 26598098     DOI: 10.1002/phar.1653

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  30 in total

1.  Population pharmacokinetics and pharmacodynamics of piperacillin in critically ill patients during the early phase of sepsis.

Authors:  Waroonrat Sukarnjanaset; Sutep Jaruratanasirikul; Thitima Wattanavijitkul
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-04-08       Impact factor: 2.745

Review 2.  Pharmacokinetic and Pharmacodynamic Considerations of Antibiotics of Last Resort in Treating Gram-Negative Infections in Adult Critically Ill Patients.

Authors:  Mojdeh S Heavner; Kimberly C Claeys; Anne M Masich; Jeffrey P Gonzales
Journal:  Curr Infect Dis Rep       Date:  2018-04-05       Impact factor: 3.725

3.  Increased vancomycin dosing requirements in sickle cell disease due to hyperfiltration-dependent and independent pathways.

Authors:  Jin Han; Xu Zhang; Jennifer Oderinde; Santosh L Saraf; Michel Gowhari; Joharah Hassan; Shivi Jain; Victor R Gordeuk; Robert E Molokie
Journal:  Haematologica       Date:  2017-05-04       Impact factor: 9.941

4.  Predictors of Augmented Renal Clearance in a Heterogeneous ICU Population as Defined by Creatinine and Cystatin C.

Authors:  Andrea M Nei; Kianoush B Kashani; Ross Dierkhising; Erin F Barreto
Journal:  Nephron       Date:  2020-05-19       Impact factor: 2.847

5.  Urinary Creatinine Clearance and Pharmacokinetics Studies: If We Can Measure It, Why Do We Estimate It?

Authors:  Catarina M Silva; Andrew A Udy; João P Baptista
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

6.  Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016.

Authors:  Andrew Rhodes; Laura E Evans; Waleed Alhazzani; Mitchell M Levy; Massimo Antonelli; Ricard Ferrer; Anand Kumar; Jonathan E Sevransky; Charles L Sprung; Mark E Nunnally; Bram Rochwerg; Gordon D Rubenfeld; Derek C Angus; Djillali Annane; Richard J Beale; Geoffrey J Bellinghan; Gordon R Bernard; Jean-Daniel Chiche; Craig Coopersmith; Daniel P De Backer; Craig J French; Seitaro Fujishima; Herwig Gerlach; Jorge Luis Hidalgo; Steven M Hollenberg; Alan E Jones; Dilip R Karnad; Ruth M Kleinpell; Younsuk Koh; Thiago Costa Lisboa; Flavia R Machado; John J Marini; John C Marshall; John E Mazuski; Lauralyn A McIntyre; Anthony S McLean; Sangeeta Mehta; Rui P Moreno; John Myburgh; Paolo Navalesi; Osamu Nishida; Tiffany M Osborn; Anders Perner; Colleen M Plunkett; Marco Ranieri; Christa A Schorr; Maureen A Seckel; Christopher W Seymour; Lisa Shieh; Khalid A Shukri; Steven Q Simpson; Mervyn Singer; B Taylor Thompson; Sean R Townsend; Thomas Van der Poll; Jean-Louis Vincent; W Joost Wiersinga; Janice L Zimmerman; R Phillip Dellinger
Journal:  Intensive Care Med       Date:  2017-01-18       Impact factor: 17.440

7.  Risk factors associated with augmented renal clearance in a mixed intensive care unit population: a retrospective study.

Authors:  Emily Bing; Kym Archambault; Alice Sananikone; Kim-Dan Nguyen; Yi Tong Fang; Caren Jabamikos; Cécile Gras; Amélie Marsot; Marc-Alexandre Duceppe; Marc M Perreault
Journal:  Int J Clin Pharm       Date:  2022-07-14

8.  Drug management in acute kidney disease - Report of the Acute Disease Quality Initiative XVI meeting.

Authors:  Marlies Ostermann; Lakhmir S Chawla; Lui G Forni; Sandra L Kane-Gill; John A Kellum; Jay Koyner; Patrick T Murray; Claudio Ronco; Stuart L Goldstein
Journal:  Br J Clin Pharmacol       Date:  2017-12-01       Impact factor: 4.335

9.  Evaluation of the Accuracy of Standard Renal Function Equations in Critically Ill Patients with Subarachnoid Hemorrhage.

Authors:  Michael A Wells; Kathryn Morbitzer; Denise H Rhoney
Journal:  Neurocrit Care       Date:  2020-06       Impact factor: 3.210

10.  A Regression Model to Predict Augmented Renal Clearance in Critically Ill Obstetric Patients and Effects on Vancomycin Treatment.

Authors:  Lian Tang; Xin-Yuan Ding; Lu-Fen Duan; Lan Li; Hao-di Lu; Feng Zhou; Lu Shi; Jian Lu; Yi Shen; Zhi-Wei Zhuang; Jian-Tong Sun; Qin Zhou; Chen-Qi Zhu; Jing-Jing Li; Yan-Xia Yu
Journal:  Front Pharmacol       Date:  2021-06-11       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.